http://www.zibb.com/all/theme/cq/Targacept+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Thu, 26 Nov 2009 12:44:10 GMTThu, 26 Nov 2009 12:44:10 GMT608831http://www.zibb.com/all/theme/cq/Targacept+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.targacept.com/wt/page/activitiesWe are committed to science education through such programs as our Brain Awareness Week lecture series and Triad BioSummer, a unique program for students interested in biotechnology and entrepreneurship. Our employees serve as curriculum advisors, guest speakers, and science fair judges.http://www.targacept.com/wt/page/activitiesTargacept Incorporatedhttp://www.apria.com/resources/1,2725,494-857108,00.htmlLOS ANGELES, Dec 8 (Reuters) - AstraZeneca PLC and Targacept Inc said on Monday that a mid-stage trial of experimental drug AZD3480 failed to demonstrate effectiveness in schizophrenia patients. Shares of Targacept fell 30 percent following the news.http://www.apria.com/resources/1,2725,494-857108,00.htmlTargacept Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=AZN&sid=145886&bx=39819.458275463-947540141Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=AZN&sid=145886&bx=39819.458275463-947540141Targacept Incorporatedhttp://www.biospace.com/company_profile.aspx?CompanyId=4378Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat various central nervous system (CNS) diseases and disorders by selectively targeting neuronal nicotinic receptors, or NNRs.http://www.biospace.com/company_profile.aspx?CompanyId=4378Targacept Incorporatedhttp://www.newratings.com/headlines/Targacept--Inc-_US87611R3066.htmlCopyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.http://www.newratings.com/headlines/Targacept--Inc-_US87611R3066.htmlTargacept Incorporatedhttp://www.euclidpartners.com/press/EUPRESSRELEASE_102304.htmlWinston-Salem, NC - Targacept, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for the proposed initial public offering of shares of its common stock. All of the shares will be issued and sold by Targacept.http://www.euclidpartners.com/press/EUPRESSRELEASE_102304.htmlTargacept Incorporatedhttp://www.omniomix.com/inthenews.php?id=70253The randomized, double-blind, single-dose trial is being conducted in the United States and is expected to enroll approximately 150 molar extraction patients. The trial includes five arms, 10, 25 and 50mg TC-2696, ibuprofen (400mg) as a positive control and placebo.http://www.omniomix.com/inthenews.php?id=70253Targacept Incorporatedhttp://www.evaluatepharma.com/CoInfo/CoInfo-TRGT.htmEvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.http://www.evaluatepharma.com/CoInfo/CoInfo-TRGT.htmTargacept Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=27777/PRNewswire-FirstCall/ -- Targacept, Inc. (Nasdaq: TRGT) today announced positive results from its Phase II clinical trial of TC-1734 (AZD3480) in age associated memory impairment (AAMI).http://www.pharmacychoice.com/News/article.cfm?Article_ID=27777Targacept Incorporatedhttp://www.mongabay.com/health/medications/citalopram_hydrobromide.htmlThis page contains recent news articles, when available, and an overview of citalopram hydrobromide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.http://www.mongabay.com/health/medications/citalopram_hydrobromide.htmlTargacept Incorporatedhttp://www.ipohome.com/marketwatch/iponews2.asp?article=4298Targacept withdraws application for IPO 3/16/2005 Targacept filed a request to withdraw its initial public offering on Wednesday. The company, which develops a new class of drugs to treat central nervous system disorders, cited difficult market conditions as the reason for withdrawing the offering.http://www.ipohome.com/marketwatch/iponews2.asp?article=4298Targacept Incorporatedhttp://www.eastoncapital.com/portfolio/lifesci/targacept.phpThese drugs offer a new way to treat various major CNS and gastrointestinal diseases and disorders including Alzheimer's Disease, depression and ulcerative colitis. Easton participated in the financing round preceding Targacept's successful initial public offering in April 2006.http://www.eastoncapital.com/portfolio/lifesci/targacept.phpTargacept Incorporatedhttp://www.gridtoday.com/03/0825/101854.htmlNews that drug discovery firm Targacept Inc. will use thousands of school computers across Forsyth County to conduct drug research in the middle of the night means an economic boon for the company.http://www.gridtoday.com/03/0825/101854.htmlTargacept Incorporatedhttp://www.kiplinger.com/apnews/XmlStoryResult.php?storyid=279212WINSTON-SALEM, N.C. (AP) - Biotech drug developer Targacept Inc. said Wednesday that it will get a $20 million milestone payment from British drugmaker AstraZeneca PLC with the continued development of an Alzheimer's disease treatment. Targacept shares rose $1.82, or 24.5 percent, to $9.http://www.kiplinger.com/apnews/XmlStoryResult.php?storyid=279212Targacept Incorporatedhttp://www.allaboutmedicalsales.com/news/1205/AstraZeneca_licensing_deal_Targacept_28.htmlThe deal is reportedly worth $300 million (£172 million) and the four-year research collaboration also allows for the development of other compounds that act on neuronal nicotinic receptors (NNRs).http://www.allaboutmedicalsales.com/news/1205/AstraZeneca_licensing_deal_Targacept_28.htmlTargacept Incorporatedhttp://www.cov.com/news/detail.aspx?news=1110WASHINGTON, D.C., January 19, 2006 - Covington & Burling represented AstraZeneca AB in its recent global licensing and research collaboration agreement with Targacept Inc.http://www.cov.com/news/detail.aspx?news=1110Targacept Incorporatedhttp://www.fiercebiotech.com/story/targacept-takes-second-shot-at-60m-ipo/2006-01-17FierceBiotech is the biotech industry daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and fda approval news.http://www.fiercebiotech.com/story/targacept-takes-second-shot-at-60m-ipo/2006-01-17Targacept Incorporatedhttp://www.lef.org/news/LefDailyNews.htm?NewsID=4755&Section=AGINGDec. 17--In laboratories locally and across the country, pharmaceutical companies are attempting to build a better mousetrap. That mousetrap is a new treatment for Alzheimer's disease, a debilitating illness that gradually robs patients of their ability to think, walk and reason.http://www.lef.org/news/LefDailyNews.htm?NewsID=4755&Section=AGINGTargacept Incorporatedhttp://www.smartbrief.com/news/fdli/industryPR-detail.jsp?id=FA090B63-8C7E-4C62-893A-2DE08AD4EA2F, a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it has initiated a Phase I clinical trial of TC-2216, its product candidate for the treatment of depression and anxiety disorders.http://www.smartbrief.com/news/fdli/industryPR-detail.jsp?id=FA090B63-8C7E-4C62-893A-2DE08AD4EA2FTargacept Incorporatedhttp://www.prnewswire.com/gh/cnoc/comp/158897.htmlIssuers of news releases and not PR Newswire are solely responsible for the accuracy of the content. Terms and conditions, including restrictions on redistribution, apply. Copyright © 1996-2006 PR Newswire Association LLC. ALL Rights Reserved. A United Business Media company.http://www.prnewswire.com/gh/cnoc/comp/158897.htmlTargacept Incorporatedhttp://www.micromedex.com/pressroom/news_feeds/?story_ID=104095&category=15Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.http://www.micromedex.com/pressroom/news_feeds/?story_ID=104095&category=15Targacept Incorporatedhttp://www.humanapress.com/index.php?option=com_journalshome&task=articledetails&category=journals&article_code=JMN:30:1:17Abstract: The potential therapeutic benefit of nicotinic ligands in a variety of neurodegenerative pathologies involving the CNS has energized research efforts to develop nicotinic acetylcholine receptor (nAChR) subtype selective ligands (Bencherif and Schmitt, 2005).http://www.humanapress.com/index.php?option=com_journalshome&task=articledetails&category=journals&article_code=JMN:30:1:17Targacept Incorporatedhttp://www.medizin-2000.de/pharma-presse/englisch/pressetexte/rhone_poulenc/rpr_alliance1.htmlCollegeville, Pa., and Antony, France -- February 9, 1999 Rhône-Poulenc Rorer Inc., a global pharmaceutical subsidiary of Rhône-Poulenc S.A. (NYSE: RP), today announced the formation of a collaborative research, development and commercialization agreement with Targacept, Inc.http://www.medizin-2000.de/pharma-presse/englisch/pressetexte/rhone_poulenc/rpr_alliance1.htmlTargacept Incorporatedhttp://www.targacept.com/wt/page/prThis portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event.http://www.targacept.com/wt/page/prTargacept Incorporatedhttp://www.apria.com/resources/1,2725,494-857246,00.htmlDec. 9--Targacept Inc. reported yesterday that it has had a second disappointing clinical result within four months regarding its most promising drug to date. Targacept, based in Piedmont Triad Research Park, was spun off from R.J. Reynolds Tobacco Co. in 2000.http://www.apria.com/resources/1,2725,494-857246,00.htmlTargacept Incorporated